Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy

Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy

312427

Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy

Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the approval by the U.S. Food and Drug Administration of Fascinate’s request for such a trial, in the form of an investigational new drug (IND) application. The study is designed to evaluate the disease-modifying potential of KM-819 in slowing or halting Parkinson’s progression in people with early and midstage disease, including…

You must be logged in to read/download the full post.